Danaher Corporation senior executive reports small share disposition for taxes. SVP of Human Resources Georgeann Couchara reported a tax-withholding disposition of 101 shares of Danaher common stock on February 24, 2026, at a price of $209.19 per share, leaving her with 3,937 directly held shares.
Danaher Corporation senior executive reports small tax-related share disposition. SVP and Chief Science Officer Jose-Carlos Gutierrez-Ramos reported a tax-withholding disposition of 344 shares of Danaher common stock at $209.19 per share. After this transaction, he directly holds 12,655 Danaher common shares.
Danaher Corporation executive Christopher Bouda, VP and Chief Accounting Officer, reported a tax-withholding disposition of 235 shares of common stock on February 24, 2026, at $209.19 per share. This was to satisfy tax obligations and was not an open-market sale.
After this transaction, Bouda directly held 8,090 common shares. He also indirectly held 677.258 common shares through a 401(k) plan, reflecting retirement-plan holdings rather than trading activity.
Danaher Corporation executive Gregory M. Milosevich reported a small tax-related share disposition. On February 24, 2026, he transferred 189 shares of common stock at a reported price of $209.19 per share to satisfy tax withholding obligations. After this transaction, he directly holds 4,910 common shares.
Danaher Corporation executive Julie A. Sawyer Montgomery reported a tax-related share disposition. On February 24, 2026, she disposed of 372 shares of Danaher common stock at a price of $209.19 per share to satisfy tax withholding obligations. After this transaction, she directly owned 17,129 shares.
Danaher Corporation Executive Vice President Christopher Paul Riley disposed of 242 shares of common stock on a tax-withholding basis. The shares were transferred at $209.19 per share to cover tax obligations, rather than as an open-market sale. After this transaction, he directly holds 15,343 shares of Danaher common stock.
Danaher Corporation files its 2025 annual report detailing a global portfolio focused on biotechnology, life sciences and diagnostics, organized into three main segments. The company emphasizes recurring-revenue lab and clinical products sold largely through direct sales across about 50 countries.
The filing highlights strategic priorities of applying the Danaher Business System, disciplined capital allocation and talent development, supported by more than 60,000 employees. It discusses a pending acquisition of Masimo Corporation, extensive R&D collaborations, and significant international exposure, with about 59% of 2025 sales from customers outside the U.S., including 11% from China.
Danaher outlines broad risk factors: economic and healthcare reimbursement pressures, intense competition and rapid technology change, supply-chain and cybersecurity vulnerabilities, regulatory and environmental obligations, AI-related uncertainties, and challenges tied to global operations and government policies. Human capital, safety, sustainability and regulatory compliance are presented as central to long‑term performance.
Danaher Corporation Executive Vice President Gregory M. Milosevich exercised employee stock options covering 1,320 shares on February 19, 2026, converting them into common stock at an exercise price of $58.5900 per share. On the same day, he sold 1,320 common shares at $208.0110 per share, leaving him with 5,099 directly owned shares. The options had vested in five equal annual installments from their original grant date, as disclosed in the footnote.
Danaher Corporation has agreed to acquire Masimo Corporation, a specialty diagnostics and patient monitoring company, in an all-cash deal. Danaher will pay $180 per Masimo share, implying a total enterprise value of about $9.9 billion including assumed debt and net of acquired cash.
The price represents roughly an 18x multiple of Masimo’s estimated 2027 EBITDA, or about 15x when including the full benefit of expected annual synergies. Masimo is expected to generate more than $530 million of EBITDA in 2027, with over $125 million in annual cost synergies and more than $50 million in annual revenue synergies by the fifth full year after closing.
Danaher expects the deal to add $0.15–$0.20 to adjusted diluted EPS in the first full year and about $0.70 by the fifth year. Masimo will operate as a standalone business within Danaher’s Diagnostics segment. The transaction is anticipated to close in the second half of 2026, funded with cash on hand and new debt, and remains subject to Masimo stockholder approval and customary regulatory clearances, including U.S. and non-U.S. antitrust and foreign investment reviews.